BIOHAVEN LTD (BHVN)

Company Profile

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 202 full-time employees. The company went IPO on 2022-09-23. The firm focuses on advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for Obsessive-Compulsive Disorder (OCD) and Spinocerebellar Ataxia (SCA), myostatin inhibition for neuromuscular diseases, and brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for immune-mediated brain disorders. Its portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and extracellular target degrader platform technology (MoDE) with potential application in neurological disorders, cancer, and autoimmune diseases.

Company Info

BIOHAVEN LTD

215 Church Street

New Haven CONNECTICUT 06510

P: 12034040410

CEO: Vlad Coric

Employees: 202

Website: https://www.biohaven.com/